{"id":"W3029640994","doi":"10.1200/jco.2020.38.15_suppl.3030","title":"Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"CD47; Medicine; Lymphoma; Immune system; Refractory (planetary science); Antibody; Cancer; Immune checkpoint; Internal medicine; Cancer research; Oncology; Pharmacology; Immunology; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001974245,0.001772465,0.002430347,0.0005569309,0.0005063489,0.001307891,0.001082595,0.001228534,0.002639674],"category_scores_gemma":[0.0007810672,0.000572635,0.001252238,0.0005502329,0.0008159022,0.001006907,0.0004173504,0.003089945,0.0011948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001133154,"about_ca_system_score_gemma":0.001646396,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001045013,"about_ca_topic_score_gemma":0.002535959,"domain_scores_codex":[0.9993839,0.0002905884,0.00002741632,0.0000734518,0.00005238412,0.0001722471],"domain_scores_gemma":[0.9991689,0.000114167,0.0001527608,0.00008039456,0.00005686341,0.0004270018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4649722,0.1379829,0.02155026,0.001286007,0.002186877,0.0009249134,0.0009693856,0.005025295,0.1217375,0.0004333422,0.007710663,0.2352205],"study_design_scores_gemma":[0.2961529,0.6631271,0.0235095,0.00005942814,0.0007205844,0.0007450217,0.0001489991,0.001453763,0.007952448,0.0002682336,0.005823142,0.00003897132],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895558,0.003274791,0.001028555,0.0004866301,0.0000887301,0.002302716,0.001195959,0.0001791134,0.001887615],"genre_scores_gemma":[0.9853532,0.002356851,0.00245901,0.001159235,0.0001912492,0.003197347,0.002884242,0.00005698539,0.002341823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002639674,"threshold_uncertainty_score":0.01044089,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07030861627519307,"score_gpt":0.3840556391609524,"score_spread":0.3137470228857593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}